NEW HAVEN, Conn., Jan. 21, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it intends to offer, subject to market, regulatory and other conditions, shares of its common stock in an underwritten public offering. The offering is expected to price before 9:30 am EST on Friday, January 22, 2010. Roth Capital Partners is acting as sole book-running manager for the offering, and Noble Financial Capital Markets and National Securities are co-managers.
